Interferon beta 1b (IFN-beta1b)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Weber-Schoendorfer (control unexposed, sick), 2009 Colvin, 2010 21.71[0.37; 7.96]5,00121not evaluable Major congenital malformations Weber-Schoendorfer (control unexposed, sick), 2009 Colvin, 2010 21.88[0.33; 10.69]4,99821not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Weber-Schoendorfer (control unexposed, sick), 2009 Fragoso a (control unexposed, sick), 2013 Nguyen (control unexposed, sick), 2019 31.32[0.31; 5.56]20668not evaluable Maternal consequences Preeclampsia Fragoso a (control unexposed, sick), 2013 17.58[1.10; 52.23]510not evaluable Gestational diabete Fragoso a (control exposed to Glatiramer), 2013 11.32[0.05; 34.93]110not evaluable Neonatal disorders Jaundice Fragoso a (control unexposed, sick), 2013 11.21[0.14; 10.79]910not evaluable Neonatal medical care Fragoso a (control unexposed, sick), 2013 110.44[0.60; 181.46]210not evaluable Long term consequences Child/Infant infections (> 1 year) Fragoso a (control unexposed, sick), 2013 12.00[0.21; 19.05]610not evaluable Child/Infant weight abnormalities (> 1 year) Fragoso a (control unexposed, sick), 2013 13.28[0.12; 86.28]110not evaluable Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Weber-Schoendorfer (control unexposed, sick), 2009 Nguyen (control unexposed, sick), 2019 21.70[0.43; 6.67]6470not evaluable Elective/induced termination of pregnancy Nguyen (control unexposed, sick), 2019 12.27[0.76; 6.76]3152not evaluable Neuro-developmental disorders ADHD (Attention deficit hyperactivity disorder): Diagnostic Fragoso a (control unexposed, sick), 2013 11.95[0.09; 43.62]210not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnostic/Risk Fragoso a (control unexposed, sick), 2013 11.95[0.09; 43.62]210not evaluable Cognitive developmental disorders/delay (> 6 years old) Fragoso a (control unexposed, sick), 2013 11.95[0.09; 43.62]210not evaluable Language disorders/delay Fragoso a (control exposed to Glatiramer), 2013 11.32[0.05; 34.93]110not evaluable Learning disorders Fragoso a (control unexposed, sick), 2013 13.28[0.12; 86.28]110not evaluable Psychomotor developmental disorders/delay Fragoso a (control exposed to Glatiramer), 2013 11.32[0.05; 34.93]110not evaluable0.0100.01.0